Patient demographics and baseline characteristics. Baseline is compared to first rituximab (RTX) treatment baseline (RTX-treated population) or initial randomization baseline (placebo-randomized and RTX-randomized populations).
| Radiographic Population | |||
|---|---|---|---|
| Characteristic | RTX-treated, n = 480 | Placebo-randomized, n = 79 | RTX-randomized, n = 105 |
| Female, n (%) | 387 (80.6) | 62 (78.5) | 89 (84.8) |
| Race, white, n (%) | 422 (87.9) | 69 (87.3) | 89 (84.8) |
| Age, yrs, mean (SD) | 52.5 (12.4) | 52.9 (10.7) | 53.5 (10.7) |
| RA disease duration, yrs, mean (SD) | 12.0 (8.1) | 10.5 (7.4) | 13.5 (9.4) |
| RF+ and/or ACPA+, n/N (%) | 393/437 (89.9) | 72/74 (97.3) | 91/96 (94.8) |
| TJC, 68 joints, mean (SD) | 34.7 (15.6) | 34.2 (16.3) | 32.6 (13.7) |
| SJC, 66 joints, mean (SD) | 23.6 (12.3) | 24.5 (13.3) | 23.9 (11.4) |
| CRP, mg/dl, mean (SD) | 3.8 (4.0) | 3.8 (3.3) | 3.4 (3.5) |
| ESR, mm/h, mean (SD) | 47.3 (26.1) | 49.6 (25.3) | 46.5 (23.9) |
| DAS28-ESR, mean (SD) | 6.9 (1.0) | 6.9 (1.0) | 6.8 (1.0) |
| HAQ-DI, mean (SD) | 1.9 (0.6) | 1.9 (0.5)* | 1.8 (0.6) |
| Baseline mTSS, mean (SD) | — | 30.9 (33.8) | 28.4 (23.6) |
↵* n = 78. RA: rheumatoid arthritis; ACPA: anticitrullinated protein antibodies; CRP: C-reactive protein; DAS28: Disease Activity Score in 28 joints; ESR: erythrocyte sedimentation rate; HAQ-DI: Health Assessment Questionnaire Disability Index; mTSS: modified Total Sharp Score; RF: rheumatoid factor; SJC: swollen joint count; TJC: tender joint count.